Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract
disease, especially in young children. Despite its global impact on healthcare, related to its …

Respiratory syncytial virus (RSV) is the leading cause of viral bronchiolitis and pneumonia in
infants and children. Currently, palivizumab is the only approved monoclonal antibody …

Respiratory syncytial virus (RSV) accounts for about 20% of all respiratory infections in
children below the age of 5 y. It is associated with up to 63% of all acute respiratory …

OBJECTIVE: Children who experience respiratory syncytial virus (RSV) lower respiratory
tract infections (LRTIs) early in life have high rates of subsequent recurrent wheezing …

Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense
RNA virus and member of the Paramyxoviridae family of the genus Pneumovirus that was …

Respiratory syncytial virus (RSV) is an important respiratory pathogen in infants and children
worldwide. Although RSV typically causes mild upper respiratory infections, it frequently …

Human respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract
infections (LRTI) in young children and elderly people worldwide. Recent significant …

Monoclonal antibodies (mAbs) are widely used in anti-inflammatory and tumor therapy.
Although effective, mAbs can cause a variety of adverse effects. An important toxicity seen …

Although it has been on the market for over a decade, confusion remains regarding the
pharmacokinetics (PK) and optimal dosing of palivizumab, a humanized IgG1κ monoclonal …